Floatz logo

ML261

Small Cell Lung Cancer (SCLC )

Moonlight Bio, IncCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

290 Active assets in the Small Cell Lung Cancer (SCLC ) cohort.

Asset / SponsorPhaseRating
Benmelstobart
Yayi He
Phase 4A
vx-970
National Cancer Institute (NCI)
Phase 2BBB
Adebelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3BBB
Veliparib
Central European Society for Anticancer Drug Research
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

ML261 is also rated in:

Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Dormant
CC
Indicative ·
43 / 100
View asset →
Gastroenteropancreatic NEC (GEP NEC)Dormant
CC
Indicative ·
43 / 100
View asset →
prostate neuroendocrine neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →